Harpoon Therapeutics

Merck HQ
#Harpoon Therapeutics #Immunotherapy #Merck #Mergers and acquisitions #Oncology

Merck continues to boost oncology pipeline through acquisitions

Merck (MSD), through a subsidiary, has agreed to acquire immunotherapy company Harpoon Therapeutics for $680 million. The acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumours. The announcement follows the news that Merck agreed… Read More

#Business & Investment #News